p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma.
about
HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment StrategiesCorrelation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic reviewMolecular Aspects of Head and Neck Cancer TherapyA quantitative histomorphometric classifier (QuHbIC) identifies aggressive versus indolent p16-positive oropharyngeal squamous cell carcinoma.Human papillomavirus (HPV) status of non-tobacco related squamous cell carcinomas of the lateral tongue.Human papillomavirus 16 oncoprotein regulates the translocation of β-catenin via the activation of epidermal growth factor receptorHLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcomeUse of p40 and p63 immunohistochemistry and human papillomavirus testing as ancillary tools for the recognition of head and neck sarcomatoid carcinoma and its distinction from benign and malignant mesenchymal processes.Detection of human papillomavirus (HPV) in clinical samples: evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomasDNA damage response and DNA repair - dog as a model?Identification of a human papillomavirus-associated oncogenic miRNA panel in human oropharyngeal squamous cell carcinoma validated by bioinformatics analysis of the Cancer Genome Atlas.Use of in situ hybridization for HPV in head and neck tumors: experience from a national reference laboratory.Current trends in the etiology and diagnosis of HPV-related head and neck cancers.The Fidelity of p16 Staining as a Surrogate Marker of Human Papillomavirus Status in Fine-Needle Aspirates and Core Biopsies of Neck Node Metastases: Implications for HPV Testing ProtocolsMutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle.A pilot study to compare the detection of HPV-16 biomarkers in salivary oral rinses with tumour p16(INK4a) expression in head and neck squamous cell carcinoma patientsHeregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.p53 expression but not p16(INK4A) correlates with human papillomavirus-associated esophageal squamous cell carcinoma in Kazakh populationA novel prediction model for human papillomavirus-associated oropharyngeal squamous cell carcinoma using p16 and subcellular β-catenin expressionSpindle cell carcinomas of the head and neck rarely harbor transcriptionally-active human papillomavirusClinical outcomes in elderly patients with human papillomavirus-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapyGenetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine.Molecular predictors of locoregional and distant metastases in oropharyngeal squamous cell carcinoma.Cyclin D1-a prognostic marker in oropharyngeal squamous cell carcinoma that is tightly associated with high-risk human papillomavirus status.Nuclear p16INK4a expression predicts enhanced radiation response in head and neck cancers.Head-and-neck squamous cell carcinoma risk in smokers: no association detected between phenotype and AHR, CYP1A1, CYP1A2, or CYP1B1 genotype.Epigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets.Prognostic biological features in neck dissection specimens.The expanding role of cytopathology in the diagnosis of HPV-related squamous cell carcinoma of the head and neck.Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives.Human papillomavirus and Epstein Barr virus in head and neck carcinomas: suggestions for the new WHO classification.Approach to metastatic carcinoma of unknown primary in the head and neck: squamous cell carcinoma and beyond.Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study.Should We De-escalate the Treatment for HPV-Positive Tumors?Human Papilloma Virus as a Biomarker for Personalized Head and Neck Cancer Radiotherapy.HPV Testing of Head and Neck Cancer in Clinical Practice.Fine-needle aspiration biopsy of HPV-related squamous cell carcinoma of the head and neck: Current ancillary testing methods for determining HPV status.Impact of p16 expression in oropharyngeal cancer in the postoperative setting: the necessity of re-evaluating traditional risk stratification.Impact of comorbidity and anemia in patients with oropharyngeal cancer primarily treated with surgery in the human papillomavirus era.Is immunohistochemical evaluation of p16 in oropharyngeal cancer enough to predict the HPV positivity?
P2860
Q26752584-6F298F77-A2A1-479D-A514-0ECC3520D44CQ26824273-8941C66A-9B6E-425C-AF2B-27498A4F3ACEQ28082815-4773A4A5-4C51-4F82-9D1A-0C049F843B89Q34379240-33B582E1-745B-43A2-A870-DF5C4BB2E889Q34659395-AE7063A3-3F52-40CF-AF87-332ACECC5628Q34944436-00C8F5EB-E2EF-42D1-B33C-61F055AB6755Q35018702-95D7F9B9-A5D0-45B2-AD9E-A148C457DC60Q35038162-64DBF35D-3807-4826-AFAF-B601250F3879Q35052911-E69E886E-4F66-4399-ADC7-E7B1893A7987Q35123713-6F90A7B4-97B6-4C61-86E6-92F98CEEE307Q35143770-4D2C5D60-4DEA-452D-B5FC-043B87A16E95Q35243985-2DEF4FE3-1AD2-409E-9B04-F13C022401B7Q35469459-8C4A7C8B-1117-4A27-83ED-F6C2FC1586F8Q35528315-BF58ED93-848E-4F23-8226-AE961282E51FQ35582737-435852D1-0F72-41CB-B284-A9B4CC8143BEQ35945485-24CDD871-B24D-4102-BA18-65BE27DB9977Q36117785-9B39EA30-D78D-407B-B176-6440DADBE985Q36793596-13EB2B9B-7137-47E9-9CF1-1FB684A90253Q36827520-410B996C-1322-4130-A2F7-06B4D6F4842FQ37083252-93DD6DF9-458F-41A5-AD40-BF59A2904ED6Q37123625-C8592478-C75F-4BED-B0C3-B53926D654BEQ37164556-BC1328E0-EAA9-43EB-8A7F-E9CE397A7E2BQ37283961-10635FC3-435C-4C56-B0AD-14AA619C2E16Q37393146-6A647396-FCEA-49B5-9306-7CDA404E0E58Q37437660-2C5435AC-088A-49E3-9487-1240F9F158FCQ37450305-68CD7CD7-A015-4803-811B-340ED8E3E63DQ37615798-5868C669-8788-467B-852C-FF8AE57CA3F0Q38043916-CB6C113A-5917-4A14-8646-E8128624840BQ38113193-75E5DFAC-C7CB-4B64-AE1D-19A44724B02DQ38195513-D8C32309-4F3D-432C-801E-5178A21B72A4Q38255620-FAC5D4FB-E278-497D-AE1A-D5EBB76D81F4Q38389252-6079F182-3836-426A-B4D1-FD81A0EA60D7Q38637666-3C5D6441-D6C8-4138-8E5D-7C90637AB82BQ38815058-56EA5B91-4F26-409B-ADEF-27F9F7A2E299Q38869435-74BBFA61-4737-41CA-AFE1-04041D263F84Q38971546-160D90C6-6708-4352-8D05-013100C3B795Q39109001-2C04B074-06C9-40DD-B76B-EE66FC44C9F4Q39543776-74A1EC35-B7A9-4915-81D1-1674FC747A0CQ39626142-168F9EC0-82B8-42FE-845D-3EE1BE0EC2C3Q40219648-B14C3B35-E64A-4B52-9F96-2297D47383ED
P2860
p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
p16 Immunohistochemistry as a ...... ngeal squamous cell carcinoma.
@ast
p16 Immunohistochemistry as a ...... ngeal squamous cell carcinoma.
@en
type
label
p16 Immunohistochemistry as a ...... ngeal squamous cell carcinoma.
@ast
p16 Immunohistochemistry as a ...... ngeal squamous cell carcinoma.
@en
prefLabel
p16 Immunohistochemistry as a ...... ngeal squamous cell carcinoma.
@ast
p16 Immunohistochemistry as a ...... ngeal squamous cell carcinoma.
@en
P2860
P1476
p16 Immunohistochemistry as a ...... ngeal squamous cell carcinoma.
@en
P2093
James S Lewis
P2860
P2888
P304
P356
10.1007/S12105-012-0369-0
P478
P577
2012-07-03T00:00:00Z